Management ChangeApr 7, 2026, 11:58 AM
Abeona Therapeutics Appoints Keith A. Goldan to Board and as Audit Committee Chair, Expanding Board to Ten Members
AI Summary
Abeona Therapeutics Inc. announced the appointment of Keith A. Goldan to its Board of Directors as a Class 1 director, effective April 1, 2026. This appointment expands the Board from nine to ten members. Mr. Goldan will also serve as Chair of the Audit Committee, bringing independent oversight to the company's financial reporting. His compensation package includes an annual cash fee of $50,000 and a one-time sign-on equity grant valued at $150,000 in restricted stock, vesting over one year, aligning his interests with long-term shareholder value.
Key Highlights
- Abeona Therapeutics expanded its Board of Directors from nine to ten members.
- Keith A. Goldan was appointed as a Class 1 director, with his term expiring at the 2026 annual meeting of stockholders.
- Mr. Goldan was also appointed to serve as Chair of the Audit Committee.
- The Board determined Mr. Goldan is an independent director under applicable Nasdaq listing rules.
- Mr. Goldan will receive an annual Board fee of $50,000 in cash.
- He will also receive a one-time sign-on equity grant of $150,000 worth of Company stock, in the form of restricted stock awards with a one-year vesting period.
Price Impact
More from ABEO